Porcine Reproductive and Respiratory Syndrome Vaccine Based on Isolate JA-142

• US 20110104201A1
• Filed: 02/20/2009
• Published: 05/05/2011
• Est. Priority Date: 04/22/1999
• Status: Active Grant

• Current Assignee: Boehringer Ingelheim Vetmedica Incorporated (C.H. Boehringer Sohn AG & Co. KG), United States Department Of Agriculture
• Original Assignee: United States Department Of Agriculture
• Inventors: Mengeling, William L., Roof, Mike, Gorcyca, David E., Vorwald, Ann, Burkhart, Kelly, Lager, Kelly
• Granted Patent: US 8,747,859 B2
• Time in Patent Office: Days
• US Class Current: 424/204.1
• CPC Class Codes: A61K 2039/5254 avirulent or attenuated
• CPC Class Codes: A61K 2039/552 Veterinary vaccine
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C12N 2770/10022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2770/10034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2770/10061 Methods of inactivation or attenuation
• CPC Class Codes: C12N 2770/10064 by serial passage
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00
• CPC Class Codes: Y10S 424/815 Viral vaccine for porcine species, e.g. swine

Abstract

Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.

Claims

1-3. -3. (canceled)

4. A method of reducing reproductive or respiratory failure in swine comprising the steps of:

providing a vaccine, said vaccine comprising at least one attenuated strain of PRRSV;

administering said vaccine to said swine.

5. The method of claim 4, said strain being selected from the group consisting of RespPRRS/Repro, JA-142, and combinations thereof.

6. The method of claim 5, said strain being JA-142.

7. The method of claim 4, said reproductive or respiratory failure resulting from infection by PRRSV.

8. The method of claim 4, said administering step occurring at least two times.

9. The method of claim 8, said times being separated by about 30 days.

10. The method of claim 4, said reproductive failure including increased incidence of abortion, increased incidence of stillborn pigs and decreased viability of liveborn pigs.

11. The method of claim 4, said administering step occurring prior to conception.

12-16. -16. (canceled)

17. An isolated DNA sequence having at least about 80% sequence identity with a sequence selected from the group consisting of SEQ ID No. 1 or SEQ ID No. 2.

18. A PRRS virus including the sequence of claim 17.

19. The virus of claim 18, said virus having been passaged a minimum of 200 times in cell culture.

20. The virus or claim 18, said virus being attenuated.

21. The virus of claim 18, said virus being substantially avirulent.

22. The virus of claim 18, said virus capable of eliciting antibody response in swine.

23. The virus of claim 22, said antibody response being specific for porcine reproductive and respiratory syndrome virus strains.

24. A vaccine comprising the DNA sequence of claim 17.

25. The vaccine of claim 24 further comprising a pharmacologically compatible carrier agent.

26. The vaccine of claim 24, said vaccine capable of eliciting antibody response in a host animal.

27. The vaccine of claim 26, said host animal including swine.

28. The vaccine of claim 26, said antibody response being specific to porcine reproductive and respiratory syndrome virus strains.

29. The vaccine of claim 28, said strains including atypical porcine reproductive and respiratory syndrome strains.

30. The DNA sequence of claim 17, wherein administration of said sequence to a host animal confers effective immunity.

31. The DNA sequence of claim 17, wherein said sequence has at least 90% sequence identity with a sequence selected from the group consisting of SEQ ID No. 1 or SEQ ID No. 2.